ethyl 5-cyclohexylisoxazole-3-carboxylate | 908856-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 5-cyclohexylisoxazole-3-carboxylate
• 英文别名: 5-cyclohexyl-isoxazole-3-carboxylic acid ethyl ester；ethyl 5-cyclohexyl-1,2-oxazole-3-carboxylate
• CAS: 908856-64-4
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: IUCHORJZHSIIFP-UHFFFAOYSA-N

物化性质

• 沸点：
  347.8±30.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-cyclohexylisoxazole-3-carboxylate 在 sodium tetrahydroborate 、 四溴化碳 、 三乙胺 、 三苯基膦 、 cesium iodide 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 为溶剂， 生成 N-[(5-cyclohexyl-1,2-oxazol-3-yl)methyl]adamantan-1-amine
  参考文献：
  名称：

  In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses

  摘要：

  Influenza viruses are respiratory pathogens that are responsible for both seasonal influenza epidemics and occasional influenza pandemics. The narrow therapeutic window of oseltamivir, coupled with the emergence of drug resistance, calls for the next-generation of antivirals. With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors. Several AM2-S31N inhibitors, including compound 10b, were discovered to have potent channel blockage, single to submicromolar antiviral activity, and favorable in vitro PK properties. The antiviral efficacy of compound 10b was also synergistic with oseltamivir carboxylate. Interestingly, binding kinetic studies (K-d, K-on, and K-off) revealed several AM2-S31N inhibitors that have similar K-d values but significantly different K-on and K-off values. Overall, this study identified a potent lead compound (10b) with improved in vitro PK properties that is suitable for the in vivo mouse model studies.

  DOI：

  10.1021/acs.jmedchem.7b01536
• 作为产物：
  描述：

  4-cyclohexyl-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester 在 盐酸羟胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 14.0h， 以56%的产率得到ethyl 5-cyclohexylisoxazole-3-carboxylate
  参考文献：
  名称：

  Compounds and compositions for use in the prevention and treatment of obesity and related syndromes

  摘要：

  本发明涉及4-羟基异亮氨酸、其同分异构体、类似物、内酯、盐和前药，以及它们的制备过程，以及包含它们的药物组合物。更具体地说，本发明涉及这些化合物在预防和治疗肥胖及相关综合症中的用途。

  公开号：

  US20060223884A1

文献信息

• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS SPHINGOSINE-1-PHOSPHATE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011017578A1

  公开（公告）日：2011-02-10

  Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物，或其立体异构体或药用可接受的盐，其中：A为Formula (II)，Q为取代的5-成员单环杂芳基团；W为CH2、O或NH；而R1、R2、R3、R4、R5、R6、m、n、t和x在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• Analogs of 4-hydroxyisoleucine and uses thereof
  申请人：Mioskowski Charles

  公开号：US20060199853A1

  公开（公告）日：2006-09-07

  The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

  本发明涉及4-羟基异亮氨酸的类似物，以及它们的内酯、药物可接受的盐和前药，其制备过程，以及包含它们的药物组合物。发明的这些类似物能够刺激葡萄糖摄取和胰岛素分泌，因此可用于预防治疗碳水化合物或脂质代谢紊乱，包括糖尿病（1型和2型糖尿病）、前驱糖尿病和代谢综合征。
• Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
  申请人：Jette Lucie

  公开号：US20100048545A1

  公开（公告）日：2010-02-25

  The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of disorders of fat metabolism and related syndromes. The invention further relates to the use of those compounds in the prevention and treatment of obesity and related syndromes including, but not limited to, the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight, and more particularly loss of body fat.

  本发明涉及4-羟基异亮氨酸、其同分异构体、类似物、内酯、盐和前药的制备方法，以及包含这些化合物的药物组合物。更具体地，本发明涉及这些化合物在预防和治疗脂肪代谢紊乱和相关综合症方面的用途。本发明还涉及这些化合物在预防和治疗肥胖和相关综合症方面的用途，包括但不限于美容治疗哺乳动物，以实现对体重，特别是体脂肪的美容有益的减少。
• HETEROCYCLIC COMPOUNDS
  申请人：Gilmore John L.

  公开号：US20110190255A1

  公开（公告）日：2011-08-04

  Disclosed are compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is Q is a substituted 5-membered monocyclic heteroaryl group; W is CH 2 , O, or NH; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及化合物I式或其立体异构体或其药学上可接受的盐，其中：A为Q为取代的5-成员单环杂芳基；W为CH2、O或NH；R1、R2、R3、R4、R5、R6、m、n、t和x在此定义。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫性疾病和血管疾病。